{"transactions":[{"id":695370,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T23:33:34.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the \"Vesting Commencement Date\"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":450000,"derivative":{"exercise_price":3.17,"expiration_date":"2036-08-02","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001610717-26-000351","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000351/form4.xml","form_type":"4"}},{"id":695369,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-05T23:33:34.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 100,000 RSUs."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001610717-26-000351","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000351/form4.xml","form_type":"4"}},{"id":946515,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2166},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946514,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946513,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":717},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946512,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Company restricted stock unit award, which represented the right to receive one share of Common Stock, that was then outstanding was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946511,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7921,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":75.5,"underlying":"Common Stock","underlying_shares":7921},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946510,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1078,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":75.5,"underlying":"Common Stock","underlying_shares":1078},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946509,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4922,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":151.5,"underlying":"Common Stock","underlying_shares":4922},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946508,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":151.5,"underlying":"Common Stock","underlying_shares":1527},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946507,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":157,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946506,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":424.5,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946505,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6702,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":16.0125,"underlying":"Common Stock","underlying_shares":6702},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946504,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3047,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":16.0125,"underlying":"Common Stock","underlying_shares":3047},"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":946503,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:51:06.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":3131,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001380","document":"tm261736-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001380/tm261736-9_4seq1.xml","form_type":"4"}},{"id":1299993,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-18T00:18:50.000Z","date":"2025-01-15","kind":"grant","planned":true,"acquired":true,"shares":54167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."}],"balance_after":54167,"derivative":{"underlying":"Common Stock","underlying_shares":54167},"source":{"system":"sec-edgar","filing":"0001104659-25-004591","document":"tm253733-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004591/tm253733-2_4seq1.xml","form_type":"4"}},{"id":1299992,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-18T00:18:50.000Z","date":"2025-01-15","kind":"grant","planned":true,"acquired":true,"shares":243750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option shall vest in equal quarterly installments over four years from the date of grant."}],"balance_after":243750,"derivative":{"exercise_price":0.64,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":243750},"source":{"system":"sec-edgar","filing":"0001104659-25-004591","document":"tm253733-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004591/tm253733-2_4seq1.xml","form_type":"4"}},{"id":1299991,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-18T00:18:50.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years."}],"balance_after":37500,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001104659-25-004591","document":"tm253733-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004591/tm253733-2_4seq1.xml","form_type":"4"}},{"id":1299990,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-18T00:18:50.000Z","date":"2025-01-16","kind":"sale","planned":true,"acquired":false,"shares":5096,"price":0.58,"value":2955.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":78296,"source":{"system":"sec-edgar","filing":"0001104659-25-004591","document":"tm253733-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004591/tm253733-2_4seq1.xml","form_type":"4"}},{"id":1299989,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-18T00:18:50.000Z","date":"2025-01-15","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 15, 2024."}],"balance_after":83392,"source":{"system":"sec-edgar","filing":"0001104659-25-004591","document":"tm253733-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004591/tm253733-2_4seq1.xml","form_type":"4"}},{"id":1301437,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-16T22:23:27.000Z","date":"2025-01-14","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of RSUs granted vested on January 14, 2025, and the remainder shall vest on January 14, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"25% of the total number of RSUs granted vested on January 14, 2025, and the remainder shall vest on January 14, 2026."}],"balance_after":2500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-25-004180","document":"tm253581-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004180/tm253581-4_4seq1.xml","form_type":"4"}},{"id":1301436,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-16T22:23:27.000Z","date":"2025-01-15","kind":"sale","planned":true,"acquired":false,"shares":952,"price":0.63,"value":599.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."}],"balance_after":70892,"source":{"system":"sec-edgar","filing":"0001104659-25-004180","document":"tm253581-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004180/tm253581-4_4seq1.xml","form_type":"4"}},{"id":1301435,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-16T22:23:27.000Z","date":"2025-01-14","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 14, 2022."}],"balance_after":71844,"source":{"system":"sec-edgar","filing":"0001104659-25-004180","document":"tm253581-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925004180/tm253581-4_4seq1.xml","form_type":"4"}},{"id":1302507,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-16T02:17:06.000Z","date":"2025-01-13","kind":"exercise","planned":true,"acquired":false,"shares":8958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"25% of the total number of RSUs granted vested on January 13, 2025, and the remainder shall vest thereafter in equal annual installments over the next two years."}],"balance_after":17917,"derivative":{"underlying":"Common Stock","underlying_shares":8958},"source":{"system":"sec-edgar","filing":"0001104659-25-003876","document":"tm253488-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925003876/tm253488-3_4seq1.xml","form_type":"4"}},{"id":1302506,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-16T02:17:06.000Z","date":"2025-01-14","kind":"sale","planned":true,"acquired":false,"shares":3330,"price":0.66,"value":2197.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023.   The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."}],"balance_after":69344,"source":{"system":"sec-edgar","filing":"0001104659-25-003876","document":"tm253488-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925003876/tm253488-3_4seq1.xml","form_type":"4"}},{"id":1302505,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-01-16T02:17:06.000Z","date":"2025-01-13","kind":"exercise","planned":true,"acquired":true,"shares":8958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 13, 2023."}],"balance_after":72674,"source":{"system":"sec-edgar","filing":"0001104659-25-003876","document":"tm253488-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925003876/tm253488-3_4seq1.xml","form_type":"4"}},{"id":1390052,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-10-07T21:48:21.000Z","date":"2024-10-01","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested as of October 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Fully vested as of October 1, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-106750","document":"tm2425739d4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924106750/tm2425739d4_4seq1.xml","form_type":"4"}},{"id":1390051,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-07T21:48:21.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":5598,"price":1.96,"value":10972.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023.   The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.92 to $2.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":63716,"source":{"system":"sec-edgar","filing":"0001104659-24-106750","document":"tm2425739d4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924106750/tm2425739d4_4seq1.xml","form_type":"4"}},{"id":1390050,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-07T21:48:21.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":8089,"price":2,"value":16178.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023.   The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.82 to $2.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":69314,"source":{"system":"sec-edgar","filing":"0001104659-24-106750","document":"tm2425739d4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924106750/tm2425739d4_4seq1.xml","form_type":"4"}},{"id":1390049,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-10-07T21:48:21.000Z","date":"2024-10-01","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of the restricted stock units (\"RSUs\") awarded to the Reporting Person on September 5, 2023."}],"balance_after":77403,"source":{"system":"sec-edgar","filing":"0001104659-24-106750","document":"tm2425739d4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924106750/tm2425739d4_4seq1.xml","form_type":"4"}},{"id":1677743,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-15","kind":"grant","planned":true,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677742,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-15","kind":"grant","planned":true,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option shall vest in equal quarterly installments over four years from the date of grant."}],"balance_after":225000,"derivative":{"exercise_price":3.02,"expiration_date":"2034-01-14","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677741,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-14","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"25% of the total number of RSUs granted vested on January 14, 2024, and the remainder shall vest thereafter in equal annual installments over the next two years."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677740,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-13","kind":"exercise","planned":true,"acquired":false,"shares":8958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years."}],"balance_after":26875,"derivative":{"underlying":"Common Stock","underlying_shares":8958},"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677739,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-16","kind":"sale","planned":true,"acquired":false,"shares":4381,"price":2.71,"value":11872.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic \"sell to cover\" transaction that did not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":27403,"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677738,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-14","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 14, 2022."}],"balance_after":31784,"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1677737,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-01-17T22:18:46.000Z","date":"2024-01-13","kind":"exercise","planned":true,"acquired":true,"shares":8958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 13, 2023."}],"balance_after":29284,"source":{"system":"sec-edgar","filing":"0001104659-24-004543","document":"tm243529-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924004543/tm243529-3_4seq1.xml","form_type":"4"}},{"id":1785781,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2023-09-07T21:59:19.000Z","date":"2023-09-05","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest on October 1, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest on October 1, 2024, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-23-099022","document":"tm2325674-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923099022/tm2325674-6_4seq1.xml","form_type":"4"}},{"id":1911266,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2023-04-28T20:15:55.000Z","date":"2023-04-26","kind":"exercise","planned":true,"acquired":false,"shares":13250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested as to 50% of the shares on April 26, 2022 and as to 50% of the shares on April 26, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested as to 50% of the shares on April 26, 2022 and as to 50% of the shares on April 26, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13250},"source":{"system":"sec-edgar","filing":"0001104659-23-052984","document":"tm2314135-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923052984/tm2314135-1_4seq1.xml","form_type":"4"}},{"id":1911265,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-04-28T20:15:55.000Z","date":"2023-04-27","kind":"sale","planned":true,"acquired":false,"shares":3944,"price":3.89,"value":15342.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to automatic sell-to-cover instructions adopted by the Reporting Person on April 26, 2021, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c). The sale was not a discretionary trade by the Reporting Person."}],"balance_after":20326,"source":{"system":"sec-edgar","filing":"0001104659-23-052984","document":"tm2314135-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923052984/tm2314135-1_4seq1.xml","form_type":"4"}},{"id":1911264,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-04-28T20:15:55.000Z","date":"2023-04-26","kind":"exercise","planned":true,"acquired":true,"shares":13250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon the vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on April 26, 2021."}],"balance_after":24270,"source":{"system":"sec-edgar","filing":"0001104659-23-052984","document":"tm2314135-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923052984/tm2314135-1_4seq1.xml","form_type":"4"}},{"id":2052317,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2023-01-19T01:09:39.000Z","date":"2023-01-14","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-23-004736","document":"tm233833-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923004736/tm233833-1_4seq1.xml","form_type":"4"}},{"id":2052316,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2023-01-19T01:09:39.000Z","date":"2023-01-13","kind":"grant","acquired":true,"shares":35833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs shall vest in equal annual installments over four years from the date of grant."}],"balance_after":35833,"derivative":{"underlying":"Common Stock","underlying_shares":35833},"source":{"system":"sec-edgar","filing":"0001104659-23-004736","document":"tm233833-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923004736/tm233833-1_4seq1.xml","form_type":"4"}},{"id":2052315,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-19T01:09:39.000Z","date":"2023-01-13","kind":"grant","acquired":true,"shares":161250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option shall vest in equal quarterly installments over four years from the date of grant."}],"balance_after":161250,"derivative":{"exercise_price":6.06,"expiration_date":"2033-01-12","underlying":"Common Stock","underlying_shares":161250},"source":{"system":"sec-edgar","filing":"0001104659-23-004736","document":"tm233833-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923004736/tm233833-1_4seq1.xml","form_type":"4"}},{"id":2052314,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-01-19T01:09:39.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":782,"price":5.74,"value":4488.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":11020,"source":{"system":"sec-edgar","filing":"0001104659-23-004736","document":"tm233833-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923004736/tm233833-1_4seq1.xml","form_type":"4"}},{"id":2052313,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Legal Officer"}}],"security":"Common Stock","published_at":"2023-01-19T01:09:39.000Z","date":"2023-01-14","kind":"exercise","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon the vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on January 14, 2022."}],"balance_after":11802,"source":{"system":"sec-edgar","filing":"0001104659-23-004736","document":"tm233833-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923004736/tm233833-1_4seq1.xml","form_type":"4"}},{"id":2288702,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2022-04-28T21:23:55.000Z","date":"2022-04-26","kind":"exercise","acquired":false,"shares":13250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vested as to 50% of the shares on April 26, 2022 and will vest as to 50% of the shares on April 26, 2023, subject to the Reporting Person's continued service to the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vested as to 50% of the shares on April 26, 2022 and will vest as to 50% of the shares on April 26, 2023, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":13250,"derivative":{"underlying":"Common Stock","underlying_shares":13250},"source":{"system":"sec-edgar","filing":"0001104659-22-052419","document":"tm2213920-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922052419/tm2213920-1_4seq1.xml","form_type":"4"}},{"id":2288701,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-04-28T21:23:55.000Z","date":"2022-04-26","kind":"sale","acquired":false,"shares":3948,"price":3.69,"value":14568.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs."}],"balance_after":9302,"source":{"system":"sec-edgar","filing":"0001104659-22-052419","document":"tm2213920-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922052419/tm2213920-1_4seq1.xml","form_type":"4"}},{"id":2288700,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-04-28T21:23:55.000Z","date":"2022-04-26","kind":"exercise","acquired":true,"shares":13250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock received upon the vesting of a portion of the restricted stock units (\"RSUs\") awarded to the Reporting Person on April 26, 2021."}],"balance_after":13250,"source":{"system":"sec-edgar","filing":"0001104659-22-052419","document":"tm2213920-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922052419/tm2213920-1_4seq1.xml","form_type":"4"}},{"id":2432168,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-19T22:43:27.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in equal annual installments over the first four years after the vesting commencement date, January 14, 2022."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-22-005540","document":"tm223926-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922005540/tm223926-1_4seq1.xml","form_type":"4"}},{"id":2432167,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-19T22:43:27.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal quarterly installments over the first four years after the vesting commencement date, January 14, 2022."}],"balance_after":45000,"derivative":{"exercise_price":6.28,"expiration_date":"2032-01-13","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-005540","document":"tm223926-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922005540/tm223926-1_4seq1.xml","form_type":"4"}},{"id":2737123,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock unit","published_at":"2021-04-28T20:32:45.000Z","date":"2021-04-26","kind":"grant","acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units will vest as to 50% of the shares on the first anniversary of the grant date and 50% of the shares on the second anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units will vest as to 50% of the shares on the first anniversary of the grant date and 50% of the shares on the second anniversary of the grant date."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-056596","document":"tm2114485-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921056596/tm2114485-2_4seq1.xml","form_type":"4"}},{"id":2737122,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-28T20:32:45.000Z","date":"2021-04-26","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years."}],"balance_after":112500,"derivative":{"exercise_price":16.98,"expiration_date":"2031-04-25","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001104659-21-056596","document":"tm2114485-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921056596/tm2114485-2_4seq1.xml","form_type":"4"}},{"id":3018318,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":71028,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":31.87,"expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":71028},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018317,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":78414,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":12.76,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":78414},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018316,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":35312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":17.25,"expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":35312},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018315,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":3972,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":31.87,"expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":3972},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018314,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":13586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":12.76,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":13586},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018313,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":23188,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects disposition of options to acquire shares of Issuer common stock (each, an \"Issuer Option\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option."}],"balance_after":0,"derivative":{"exercise_price":17.25,"expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":23188},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018312,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018311,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":21938,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21938},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018310,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3018309,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-10-01T17:00:06.000Z","date":"2020-10-01","kind":"disposition_to_issuer","acquired":false,"shares":28795,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the \"Merger Agreement\"), by and among Johnson & Johnson, Vigor Sub, Inc. (\"Merger Sub\") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on October 1, 2020.  Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-20-010053","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020010053/edgar.xml","form_type":"4"}},{"id":3078639,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-07-21T16:02:02.000Z","date":"2020-07-17","kind":"exercise","acquired":false,"shares":2437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":21938,"derivative":{"underlying":"Common Stock","underlying_shares":2437},"source":{"system":"sec-edgar","filing":"0001179110-20-008393","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020008393/edgar.xml","form_type":"4"}},{"id":3078638,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-21T16:02:02.000Z","date":"2020-07-20","kind":"sale","acquired":false,"shares":1087,"price":33.95,"value":36903.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":28795,"source":{"system":"sec-edgar","filing":"0001179110-20-008393","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020008393/edgar.xml","form_type":"4"}},{"id":3078637,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-21T16:02:02.000Z","date":"2020-07-17","kind":"exercise","acquired":true,"shares":2437,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":29882,"source":{"system":"sec-edgar","filing":"0001179110-20-008393","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020008393/edgar.xml","form_type":"4"}},{"id":3095026,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-07-01T21:14:58.000Z","date":"2020-06-29","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 29, 2021."}],"balance_after":45000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-080017","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000110465920080017/a4.xml","form_type":"4"}},{"id":3095025,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-01T21:14:58.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":6811,"price":35.1,"value":239066.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":27445,"source":{"system":"sec-edgar","filing":"0001104659-20-080017","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000110465920080017/a4.xml","form_type":"4"}},{"id":3095024,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-07-01T21:14:58.000Z","date":"2020-06-29","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018."}],"balance_after":34256,"source":{"system":"sec-edgar","filing":"0001104659-20-080017","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000110465920080017/a4.xml","form_type":"4"}},{"id":3110307,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-15T17:25:14.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, 15,000 Restricted Stock Units will vest on June 11, 2021."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-20-007360","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020007360/edgar.xml","form_type":"4"}},{"id":3110306,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-06-15T17:25:14.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":6756,"price":30.15,"value":203693.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":19256,"source":{"system":"sec-edgar","filing":"0001179110-20-007360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020007360/edgar.xml","form_type":"4"}},{"id":3110305,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-06-15T17:25:14.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018."}],"balance_after":26012,"source":{"system":"sec-edgar","filing":"0001179110-20-007360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020007360/edgar.xml","form_type":"4"}},{"id":3172301,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-04-21T16:21:30.000Z","date":"2020-04-17","kind":"exercise","acquired":false,"shares":2438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":24375,"derivative":{"underlying":"Common Stock","underlying_shares":2438},"source":{"system":"sec-edgar","filing":"0001179110-20-005001","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020005001/edgar.xml","form_type":"4"}},{"id":3172300,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-21T16:21:30.000Z","date":"2020-04-20","kind":"sale","acquired":false,"shares":1124,"price":28.97,"value":32562.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":11012,"source":{"system":"sec-edgar","filing":"0001179110-20-005001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020005001/edgar.xml","form_type":"4"}},{"id":3172299,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-04-21T16:21:30.000Z","date":"2020-04-17","kind":"exercise","acquired":true,"shares":2438,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":12136,"source":{"system":"sec-edgar","filing":"0001179110-20-005001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020005001/edgar.xml","form_type":"4"}},{"id":3220152,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-09T17:14:57.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001179110-20-003311","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020003311/edgar.xml","form_type":"4"}},{"id":3220151,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-09T17:14:57.000Z","date":"2020-03-06","kind":"sale","acquired":false,"shares":5302,"price":29,"value":153758.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":9698,"source":{"system":"sec-edgar","filing":"0001179110-20-003311","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020003311/edgar.xml","form_type":"4"}},{"id":3220150,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-09T17:14:57.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001179110-20-003311","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020003311/edgar.xml","form_type":"4"}},{"id":3262568,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-19T18:43:25.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":6892,"price":31.54,"value":217373.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-20-001910","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001910/edgar.xml","form_type":"4"}},{"id":3270216,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-14T18:52:45.000Z","date":"2020-02-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-20-001661","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001661/edgar.xml","form_type":"4"}},{"id":3270215,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-14T18:52:45.000Z","date":"2020-02-13","kind":"sale","acquired":false,"shares":3108,"price":30.03,"value":93333.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":6892,"source":{"system":"sec-edgar","filing":"0001179110-20-001661","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001661/edgar.xml","form_type":"4"}},{"id":3270214,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-14T18:52:45.000Z","date":"2020-02-12","kind":"exercise","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001179110-20-001661","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001661/edgar.xml","form_type":"4"}},{"id":3279596,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-11T19:04:57.000Z","date":"2020-02-07","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to certain criteria, the stock option will vest and become exercisable with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":75000,"derivative":{"exercise_price":31.87,"expiration_date":"2030-02-07","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001179110-20-001472","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001472/edgar.xml","form_type":"4"}},{"id":3279595,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-11T19:04:57.000Z","date":"2020-02-07","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the officer continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the officer continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":37500,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001179110-20-001472","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020001472/edgar.xml","form_type":"4"}},{"id":3302735,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-24T16:41:57.000Z","date":"2020-01-22","kind":"sale","acquired":false,"shares":1577,"price":28.98,"value":45701.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-20-000763","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020000763/edgar.xml","form_type":"4"}},{"id":3305143,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-01-22T17:16:39.000Z","date":"2020-01-17","kind":"exercise","acquired":false,"shares":2437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":26813,"derivative":{"underlying":"Common Stock","underlying_shares":2437},"source":{"system":"sec-edgar","filing":"0001179110-20-000702","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020000702/edgar.xml","form_type":"4"}},{"id":3305142,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-22T17:16:39.000Z","date":"2020-01-21","kind":"sale","acquired":false,"shares":860,"price":30.08,"value":25868.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1577,"source":{"system":"sec-edgar","filing":"0001179110-20-000702","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020000702/edgar.xml","form_type":"4"}},{"id":3305141,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-01-22T17:16:39.000Z","date":"2020-01-17","kind":"exercise","acquired":true,"shares":2437,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":2437,"source":{"system":"sec-edgar","filing":"0001179110-20-000702","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911020000702/edgar.xml","form_type":"4"}},{"id":3389118,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-10-23T17:19:47.000Z","date":"2019-10-21","kind":"sale","acquired":false,"shares":6814,"price":14.4,"value":98121.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.30 to $14.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-19-011211","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019011211/edgar.xml","form_type":"4"}},{"id":3390097,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-10-21T16:11:30.000Z","date":"2019-10-17","kind":"exercise","acquired":false,"shares":9750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years."}],"balance_after":29250,"derivative":{"underlying":"Common Stock","underlying_shares":9750},"source":{"system":"sec-edgar","filing":"0001179110-19-011132","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019011132/edgar.xml","form_type":"4"}},{"id":3390096,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-10-21T16:11:30.000Z","date":"2019-10-18","kind":"sale","acquired":false,"shares":2936,"price":13.83,"value":40604.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":6814,"source":{"system":"sec-edgar","filing":"0001179110-19-011132","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019011132/edgar.xml","form_type":"4"}},{"id":3390095,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-10-21T16:11:30.000Z","date":"2019-10-17","kind":"exercise","acquired":true,"shares":9750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17,2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":9750,"source":{"system":"sec-edgar","filing":"0001179110-19-011132","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019011132/edgar.xml","form_type":"4"}},{"id":3527496,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-05-14T18:55:24.000Z","date":"2019-04-13","kind":"disposition_to_issuer","acquired":false,"shares":4724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed on April 16, 2019 is amended by this Form 4/A to correctly reflect the reporting person's disposal of 4,724, not 4725, shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4 filed on April 16, 2019 is amended by this Form 4/A to correctly reflect the reporting person's ownership balance of 10,384, not 10,383, shares of common stock."}],"balance_after":10384,"source":{"system":"sec-edgar","filing":"0001179110-19-006032","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019006032/edgar.xml","form_type":"4/A","original_submission_date":"2019-04-16"}},{"id":3544233,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-05-01T16:04:40.000Z","date":"2019-04-29","kind":"sale","acquired":false,"shares":10384,"price":14.77,"value":153371.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $14.50 to $15.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-19-005357","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019005357/edgar.xml","form_type":"4"}},{"id":3554974,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-04-16T17:03:40.000Z","date":"2019-04-13","kind":"disposition_to_issuer","acquired":false,"shares":4725,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10383,"source":{"system":"sec-edgar","filing":"0001179110-19-004992","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019004992/edgar.xml","form_type":"4"}},{"id":3649402,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-02-19T16:52:06.000Z","date":"2019-02-14","kind":"sale","acquired":false,"shares":703,"price":13.1,"value":9209.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":15108,"source":{"system":"sec-edgar","filing":"0001179110-19-002086","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019002086/edgar.xml","form_type":"4"}},{"id":3656188,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-14T16:26:54.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-19-001905","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019001905/edgar.xml","form_type":"4"}},{"id":3656187,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-02-14T16:26:54.000Z","date":"2019-02-13","kind":"sale","acquired":false,"shares":2938,"price":12.7,"value":37312.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":15811,"source":{"system":"sec-edgar","filing":"0001179110-19-001905","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019001905/edgar.xml","form_type":"4"}},{"id":3656186,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-02-14T16:26:54.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Restricted Stock Units convert into common stock on a one-for-one basis."}],"balance_after":18749,"source":{"system":"sec-edgar","filing":"0001179110-19-001905","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019001905/edgar.xml","form_type":"4"}},{"id":3660014,"issuer":{"id":146313,"kind":"organization","name":"MOMENTA PHARMACEUTICALS INC","symbol":"MNTA"},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-13T16:45:13.000Z","date":"2019-02-11","kind":"grant","acquired":true,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted by the issuer pursuant to the issuer's 2013 Incentive Award Plan, as amended and restated."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become exercisable with respect to 23,000 shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.  All vesting is subject to Alejandra Carvajal's continued service to the Company through the applicable vesting date."}],"balance_after":92000,"derivative":{"exercise_price":12.76,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001179110-19-001838","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235010/000117911019001838/edgar.xml","form_type":"4"}}],"next_cursor":"2019-02-13T16:45:13.000000Z,3660014"}